- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 24,100 | 0,00 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
21.11.2025 / 12:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| EYEPOINT | 13,525 | +1,42 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| AMARIN | 12,400 | -1,59 % | Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,310 | -2,36 % | SELLAS partners with IMPACT-AML for European SLS009 trials | ||
| CATALYST PHARMACEUTICALS | 19,005 | -1,53 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 425,50 | -0,47 % | Madrigal Pharmaceuticals stock maintains Buy rating at Goldman Sachs | ||
| ANI PHARMACEUTICALS | 73,00 | +0,69 % | ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| DOGECOIN CASH | - | - | Dogecoin Cash, Inc. Becomes Among the First U.S. Public Companies to Complete a FINRA-Notified Blockchain-Linked Security Distribution | MESQUITE, NV, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Mesquite, NV January 9, 2026 - Dogecoin Cash, Inc. (OTC: DOGP) today announced that the Financial Industry Regulatory Authority (FINRA) has publicly... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | Blum Holdings: Blüm Holdings Announces $3.05 Million Debt Conversion | ||
| BMP PHARMA TRADING | 4,720 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: Konzern weiterhin auf Erfolgskurs - Die Gesellschaft steigert das operative Halbjahresergebnis im Geschäftsjahr 2025 | DJ PTA-News: B.M.P. Pharma Trading AG: Konzern weiterhin auf Erfolgskurs - Die Gesellschaft steigert das operative Halbjahresergebnis im Geschäftsjahr 2025
Unternehmensmitteilung für den Kapitalmarkt... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,195 | -5,65 % | Theriva Biologics, Inc.: Theriva Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | - EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 7,100 | +1,28 % | Kazia Therapeutics Limited: Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,125 | 0,00 % | Allergy Therapeutics expects revenue growth after "strong" first half | ||
| ACURA PHARMACEUTICALS | - | - | Acura Pharmaceuticals passt Vereinbarungen mit AD Pharma an und verlängert Kreditlaufzeit |
Das Unternehmen MERUS LABS INTERNATIONAL INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.